-INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a chronic disease that has become pandemic, as it affects between 20% and 30% of the general adult population of most Westernized countries.
Although most cases of NAFLD follow a benign course, approximatively 20% evolve into an aggressive form termed non-alcoholic steatohepatitis (NASH), in which inflammation in the liver can cause hepatocyte damage with or without fibrosis [1] . NASH typically entails high levels of hepatic lipid peroxidation, oxidative stress, apoptosis and production of pro-inflammatory and pro-fibrotic cytokines that induce necroinflammation and ultimately fibrosis [2, 3] . Progressive evolution of hepatic inflammation and fibrosis can lead to cirrhosis, liver failure or hepatocellular carcinoma, with end-stage liver disease due to NASH being anticipated as the leading indication for liver transplantation in subsequent years [4, 5] . Generally, pathogenic drivers and rates of progression of NAFLD are not identical among all patients, and thus NASH should not be thought of as an orderly progression of stages. Although certain advances have led to a better understanding of the pathogenesis of NAFLD and to the identification of therapeutic targets and drugs, no therapy for NASH exists other than lifestyle modifications (to ensure weight loss) and bariatric surgery for morbidly obese patients [6, 7] .
Although drug development for NASH has accelerated in recent years, the choice of animal models remains one of the major issues for the assessment of drug candidates at the initial steps of preclinical development. Indeed, an appropriate animal model should recreate as closely as possible the pathological patterns, metabolic and transcriptomic features, and histological alterations found in human NASH. Several preclinical mouse and rat models for NASH are currently available, with various approaches based on genetic modification, e.g., ob -/ob -or db -/db -mice with leptin and leptin receptor deficiency, respectively, diet induction, e.g., high-fat/cholesterol/fructose diet or methionine/cholinedeficient diet, or chemical induction, e.g., thioacetamide or carbon tetrachloride [2, 8, 9] . Each of these models can be used separately or in combination. Although these models are mandatory tools for assessing the efficacy of candidate compounds before proceeding to clinical trials, the majority do not entirely replicate human NASH features, i.e., they may lack fibrosis or lack insulin resistance in dietinduced models [10] . Another important issue that may hinder preclinical assessment of NASH drug candidates is the large amount of resources and time needed to bring a model to a standard suitable for experimental studies, as most of the existing models require several weeks, ranging from 6 to 40
weeks, to create a NASH phenotype [2] . Hence, there is need for animal models that rapidly develop an initial, economical, and rapid preclinical evaluation of drug candidates.
To address the issues associated with current NASH models, we developed, characterized, and evaluated the utility of a rapid-onset and inexpensive murine model of NASH based on dietary induction. Toward this goal, we customized a high-fat diet (60% of calories) containing high levels of cholesterol (1.25%) and cholic acid (0.5%), components that have been used separately or in combination to promote hepatic steatosis and lipotoxicity [11] [12] [13] . To promote cholesterol uptake by the liver, we also supplemented the drinking water with 2% hydroxypropyl-β-cyclodextrin (CDX), a cyclic oligosaccharide that has high affinity for sterols [14] . Beginning at age 8 weeks, C57BL/6J mice were fed this high-fat, high-cholesterol, cholate and CDX (HFCC-CDX) diet for 1 or 3 weeks, after which parameters related to hepatic steatosis, liver inflammation, liver fibrosis, and glucose metabolism were measured. In parallel, another group of experimental mice were fed the HFCC-CDX diet for 3 weeks, but after 1 week they were also treated daily with liraglutide, a GLP-1 analog currently in advance clinical development for NASH [15] . These groups were then compared with respect to NASH phenotype.
-MATERIALS AND METHODS

-Animals, diets and drugs
All animal procedures were performed in accordance with the guidelines of the Committee on Animals of the Midi-Pyrénées Ethics Committee on Animal Experimentation and with the French Ministry of Agriculture license. Wild-type C57BL/6J male mice were caged in animal rooms with 12-h light/12-h dark cycle and ad libitum access to water and diet. At the initiation of the dietary intervention, all animals were 8 weeks old and were fed a chow diet (V1534-000, Ssniff, Germany). During the experimental period, mice were provided with either the chow diet for 3 weeks (CD control group) or a custom diet high in fat (60 kcal%), cholesterol (1.25%) and cholic acid (0.5%) (D11061901, Research Diet, Denmark) as well as 2% CDX (Fisher Scientific, France) in drinking water (HFCC-CDX group).
For the last 2 weeks of the 3-week period, groups of mice fed the HFCC-CDX diet received a daily intraperitoneal injection of either liraglutide (Victoza®, Novo Nordisk, Denmark) at 100 μ g/kg body weight or vehicle (phosphate-buffered saline). and then used for blinded histopathological NAFLD activity scoring based on a scoring system adapted from Kleiner et al. [16] . Hepatocellular steatosis, liver inflammation, and lobular fibrosis were qualitatively assessed and ranked with a score, and a total NAFLD activity score was then calculated for each animal by summing the scores for steatosis, inflammation, and lobular fibrosis.
-Liver histology
-Liver lipid content
Total lipids were measured in liver tissue after extraction with chloroform:methanol (2:1) according to
Folch et al. [17] . Briefly, 100 mg liver tissue was homogenized in 900 
-Measuring liver ROS and TBARS
ROS in liver were assayed according to the protocol of Szabados et al. [18] . 
-RNA extraction and real-time quantitative PCR analysis
Total RNA was prepared from liver tissue using QIAzol lysis reagent (QIAGEN, Germantown, USA).
Extracted RNAs were suspended in DNase/RNase-free water, and the concentration of each sample was calculated after measuring absorbance at 260 nm using a NanoDrop™ spectrophotometer (Thermo Scientific™, Waltham, USA). Reverse transcription of mRNA (1 µg) was performed using M-MLV Reverse Transcriptase (ThermoFisher, Waltham, USA) in the presence of a random primer (oligo(dT), 2 µl, 500 µg/ml; Promega, Madison, WI, USA) and 0.5 µl RNaseOUT™ (ThermoFisher). and 60°C for 30 s, for 40 cycles. mRNA levels were calculated relative to the average value obtained for the housekeeping gene and further normalized to the relative expression of the respective controls (i.e., wild-type mice fed the CD diet).
-Analysis of plasma samples
Commercial colorimetric kits (Biolabo SA) based on the CHOD-PAP and GPO-PAP detection methods, coupling enzymatic reaction, and spectrophotometric detection of reaction end-products were used for determination of plasma triglycerides and cholesterol levels. Plasma ALT and AST were determined using a COBAS-MIRA+ biochemical analyzer (Anexplo facility, Toulouse, France).
Levels of inflammatory cytokines (IL6, IL10, TNF-α and MCP-1) were assayed in mouse plasma samples collected by cardiac puncture upon sacrifice; a Milliplex mouse cytokine magnetic kit (Millipore, France) was used according to the manufacturer's instructions.
-Oral glucose tolerance test
After an overnight fast, mice were given an oral gavage glucose load (3 mg • g -1 body weight). Blood glucose in samples obtained from the tail vein was assayed with a portable glucometer 30 min before oral glucose loading and at 0, 15, 30, 45, 60, 90 and 120 min thereafter. Insulin concentration in plasma (5 µl sample) was determined 30 min before and 15 min after glucose loading using an ELISA kit (Mercodia, Uppsala, Sweden).
-Analysis of insulin signaling
To analyze the liver insulin signaling pathway, mice received insulin at 1 mU mice were euthanized and the liver rapidly dissected. Each individual mouse liver was homogenized using the Precellys lysing kit in RIPA buffer containing a protease inhibitor cocktail (leupeptin, aprotinin). Protein concentration in thawed samples (stored at -80°C) was measured using the Bradford method (Bio-Rad).
The percentage of phospho-Ser-473-Akt to total Akt was determined by capillary western blotting using the ProteinSimple Wes System with 12-to 230-kDa Wes Separation Module capillary cartridges (ProteinSimple, Santa Clara, CA, USA). A mouse monoclonal antibody specific for Akt (#2920S, Cell Signaling) and rabbit polyclonal antibody specific for phosphorylated Akt (pAkt, Ser473, #9271T, Cell Signaling) were used at a dilution of 1:100. Anti-mouse and anti-rabbit detection modules for Wes (ProteinSimple) kits included Luminol-S, peroxide, antibody diluent, streptavidin-coupled horseradish peroxidase, and anti-mouse and anti-rabbit secondary antibodies. Sample proteins (5 ng per each condition) were allowed to separate via the capillary technology and were analyzed based on chemiluminescence, which was transformed into digital images depicting bands as observed in western blots. The abundance of each of total Akt and pAkt was determined using Compass software (ProteinSimple). The normalized data are expressed as the percentage of pAkt to total Akt.
-Statistical analysis
Data are expressed as the mean ± SEM. Differences between groups were assessed using the Student's t-test or one-way analysis of variance followed by Bonferroni post-hoc test when necessary.
The data were analyzed using Prism V.5.01 for Windows (GraphPad Software, San Diego, CA, USA).
The level of significance was defined as p < 0.05.
-RESULTS
-HFCC-CDX feeding for 1 week causes hepatic steatosis and inflammation that is associated with systemic inflammation.
We first evaluated the ability of the HFCC-CDX diet to induce NASH features within 1 week. C57BL6/J male mice (8 weeks old) were divided into two groups and fed either a chow diet (CD) or HFCC-CDX diet for 1 week. The livers of mice fed HFCC-CDX were grossly enlarged (∼30% increase in liver weight; Figure 1A ) and pale in color ( Figure 1B ). Liver histological analyses were performed using Oil Hepatic cholesterol and free fatty acid overload induce oxidative stress that drives lipotoxicity and cellular injury, which are considered critical factors in NASH pathogenesis [19] . We thus analyzed whether the HFCC-CDX diet could induce hepatic oxidative stress and lipid peroxidation by measuring the production of reactive oxygen species (ROS) and thiobarbituric acid response substrates (TBARS), which are byproducts of lipid peroxidation [20] . Both hepatic ROS and TBARS levels were significantly higher in the HFCC-CDX-fed group, with a ∼30% and ∼300% increase, respectively, compared with the CD group ( Figure 1E and 1F) . We further analyzed hepatic expression of candidate genes associated with NASH pathology. Confirming the inflammatory response to HFCC-CDX feeding, expression of genes encoding inflammatory cytokines and macrophages chemotactic factors,
including TNFα, MCP-1, IL1β and F4/80, were significantly increased in HFCC-CDX mice compared with CD mice ( Figure 1G ). Interestingly, the hepatic expression of certain genes related to fibrosis, e.g., Col1α1 and TGFβ, was also significantly increased in the HFCC-CDX group ( Figure 1G ), suggesting that the fibroproliferative response was also activated.
We then analyzed NASH-related systemic effects. As anticipated, mice fed HFCC-CDX for 1 week had a dyslipidemic profile, with ∼200% higher plasma triglycerides and ∼60% higher cholesterol levels compared with the CD mice ( Figure 2A) ; also, the plasma levels of the transaminases alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were dramatically increased, reflecting liver injury ( Figure 2B ). Moreover, the HFCC-CDX mice had significantly higher levels of plasma inflammatory cytokines, including interleukin-6 (IL6, ∼600%, p < 0.05) and monocyte chemoattractant protein 1 (MCP-1, ∼350%, p < 0.05), whereas a trend toward higher IL10 (∼150%) and tumor-necrosis factor α (TNF-α, ∼170%) was also observed ( Figure 2C) . Accordingly, the HFCC-CDX diet dramatically increased the inflammatory index based on differences in inflammatory cytokines levels between mice fed the CD diet or HFCC-CDX diet ( Figure 2D ).
Next, we found that HFCC-CDX feeding for 1 week did not affect oral glucose tolerance ( Figure 2E) and plasma insulin level ( Figure 2F ). However, direct liver stimulation via injection of insulin into the portal vein caused a significant reduction in phosphorylation of the kinase Akt in the HFCC-CDX group ( Figure 2G ), reflecting impaired insulin signaling. These results indicated that HFCC-CDX feeding for 1
week established hepatic insulin resistance that had yet to translate into impaired whole-body glucose metabolism. Overall, these data revealed that HFCC-CDX feeding for 1 week is sufficient to induce some important NASH features, including hepatic steatosis and inflammation.
-Treatment with liraglutide reverses NASH features and reduces systemic inflammation and insulin resistance induced by the HFCC-CDX diet
To evaluate whether a longer-term dietary intervention could accentuate the NASH features that were observed after 1 week of feeding the HFCC-CDX diet (Figure 1 and 2) , a group of mice was fed the diet for two additional weeks (HFCC-CDX group). In parallel, to assess the relevance of this dietary NASH model, we included another group fed the HFCC-CDX diet for 3 weeks to assess whether oncedaily treatment with liraglutide for the last 2 weeks could confer protection against NASH [HFCC-CDX-
Liraglutide is a GLP-1 analog licensed for the treatment of type 2 diabetes and is currently in advanced clinical development for NASH [2, 15] . Among all mice used in this experiment, one-third were fed the HFCC-CDX diet and injected with vehicle (phosphate-buffered saline; liraglutide control group) for the last 2 weeks of feeding, and another one-third were fed the HFCC-CDX diet and injected with liraglutide; the other one-third comprised the control mice (no steatosis) that were fed the CD diet.
Total caloric intake was greater for the HFCC-CDX group as compared with the CD group ( Figure 3A ), but there was no difference in body weight gain between these two groups throughout the feeding period ( Figure 3B ). As expected, however, liraglutide treatment reduced caloric intake, which was associated with body weight loss compared with non-treated mice (HFCC-CDX group, Figure 3A , B).
Compared with HFCC-CDX feeding for 1 week, the NASH phenotype continued to worsen at 3 weeks, as manifested by hepatomegaly ( Figure 3C ), fatty liver ( Figure 3D ), and increased content of hepatic triglycerides, cholesterol, and NEFAs ( Figure 3E ). Treatment with liraglutide significantly reduced liver weight and hepatic triglycerides to a level similar to that of the CD group.
Liver histology was performed ( Figure 3F ), and the NAFLD activity score was calculated for each of the HFCC-CDX and HFCC-CDX-Lira groups ( Figure 3G) ; the total score comprised the sum of scores for each of hepatocellular steatosis, interstitial inflammation, and lobular fibrosis. For the HFCC-CDX group, steatosis ranged from score-2 limited to Zone-2/3 to a score-3 pan-lobular steatosis. The Concerning NASH-related systemic features, treatment of the HFCC-CDX mice with liraglutide normalized plasma triglyceride levels to those of the CD group, although liraglutide had no effect on the HFCC-CDX-induced hypercholesterolemia ( Figure 4A ) or on plasma transaminases ( Figure 4B ).
The HFCC-CDX-induced increase in levels of plasma inflammatory cytokines was sustained after 3 weeks of the dietary period, and liraglutide significantly reduced the levels of both IL6 and IL10 ( Figure   4C ), which translated into a significant reduction of the inflammatory index as compared with the nontreated HFCC-CDX group ( Figure 4D ). Concerning glucose metabolism, results of the oral glucose tolerance test did not differ between the HFCC-CDX and CD groups ( Figure 4E ), although the HFCC-CDX diet caused insulin resistance, as shown by the increased basal and glucose-stimulated insulin levels ( Figure 4F ), and impaired hepatic insulin signaling ( Figure 4G ). As expected, liraglutide treatment improved glucose tolerance ( Figure 4E ) and protected from HFCC-CDX-induced insulin resistance ( Figure 4F and 4G).
-DISCUSSION
For purposes of preclinical assessment, we characterized and validated a novel dietary mouse model that recapitulates the major hallmarks of human NASH within 3 weeks of the diet. In the proposed model, the C57BL/6 genetic background was chosen because it is more susceptible to liver injury than other inbred strains [21] [22] [23] . The HFCC-CDX diet used in this model was formulated to be high in fat (60 kcal%), cholesterol (1.25%) and cholic acid (0.5%) and was supplemented with 2% CDX in drinking water, with the objective of potentiating NASH development via the ability of cholic acid and CDX to stimulate the intestinal absorption of cholesterol and lipids and to increase hepatic cholesterol content and inflammation [11, 12, 14] . The NASH features reproduced in this model include liver steatosis (characterized by excessive accumulation of triglycerides, cholesterol and NEFAs within the first week of the diet), a marked rise in the level of the liver-impairment marker ALT, oxidative stress, and hepatic inflammation and progression to mild fibrosis within 3 weeks. This model also exhibited transcriptomic and metabolic alterations associated with the human disease, including insulin resistance, dyslipidemia, and systemic inflammation.
For a short period of dietary intervention (e.g., 3 weeks in our study), none of the current diet-induced mouse models of NAFLD/NASH can recapitulate the human pathogenesis as well our HFCC-CDX model. For instance, feeding C57BL/6J mice a high fat (60% kcal) diet containing cholesterol (1.25%) and cholate (0.5%) for 12 weeks was found to induce steatosis, inflammation, and fibrosis associated with dyslipidemia, lipid peroxidation, oxidative stress, and insulin resistance [24] , whereas we found that a similar NASH phenotype was induced in just 3 weeks of feeding with the HFCC-CDX diet.
Likewise, Western-type diets of varying composition with respect to fat (21-45 kcal%), cholesterol (0.1-2%), and sugars (e.g., 20% fructose) closely mimic the pathogenesis of human NASH, i.e., insulin resistance, inflammation and liver fibrosis; regardless of the composition, however, the NASH phenotype manifested only after a relatively long-term diet duration of 8 to 30 weeks [2, 9] . C57BL/6J mice fed a methionine-and choline-deficient diet develop a NASH phenotype in the shortest time compared with all previous NASH models, with hepatic steatosis by 2-4 weeks and progression to inflammation and fibrosis shortly thereafter, although animals lose weight and do not develop insulin resistance [25, 26] . In contrast, the present HFCC-CDX dietary model more closely recapitulates the NASH-associated metabolic dysfunctions of humans, including insulin resistance. One limitation of the HFCC-CDX dietary model for NASH compared to the disease development in humans is that mice do not become obese.
We also used our 3-week HFCC-CDX dietary mouse model to test the therapeutic efficacy of liraglutide. Indeed, besides the attributes of improving glucose metabolism, reducing food intake, and promoting weight loss, certain other systemic and hepatic effects of liraglutide have been documented in preclinical and clinical studies, and hence liraglutide has been the subject of extensive evaluation as a therapeutic candidate for NAFLD [27, 28] . Our present study revealed that once-daily injection of liraglutide for 2 weeks decreased caloric intake and body weight, improved glucose tolerance, and protected from HFCC-CDX-induced insulin resistance, which are well-known effects of liraglutide in humans [27, 28] . In addition, we observed that liraglutide could resolve hypertriglyceridemia and reduce hepatic steatosis, oxidative stress, and systemic and hepatic inflammation but not fibrosis, results that are in general agreement with the effects of liraglutide documented in preclinical studies with mice [29] [30] [31] and clinical trials for NASH [32] [33] [34] . In NAFLD patients, plasma ALT and AST levels have been found to decrease gradually during liraglutide treatment [32] [33] [34] . In our experimental setting, liraglutide could indeed significantly decrease the total NAFLD activity score but could not counter the HFCC-CDX-induced increase in plasma ALT and AST, in agreement with results from another dietary mouse model of NASH [30] . Whether longer-term treatment with liraglutide can reduce transaminase levels in mice -as observed in human studies -will require a different experimental design. In this respect, the objective of the present work was to provide a preclinical model to facilitate rapid screening of therapeutic targets to treat NASH, but future studies must explore whether HFCC-CDX fed over a longer period might promote progression to more severe stages of NASH, such as advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Also, we chose the mouse strain C57BL/6 based on its reasonable cost and susceptibility to diet-induced liver steatosis compared wither other inbred strains [21] [22] [23] . Future studies could investigate the effect of the HFCC-CDX diet on isogenic strains selected for their susceptibility to develop diet-induced NASH or genetic mouse models that are predisposed to developing a fatty liver [35] [36] [37] .
In summary, although drug-development research for NASH is intense and advancing rapidly, here we 
